Literature DB >> 2104432

[Evaluation of the anti-arrhythmia effectiveness of Phenazolinum Polfa in paroxysmal atrial fibrillation].

M Srzednicki1, Z Sadowski, A Kulikowski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2104432

Source DB:  PubMed          Journal:  Pol Tyg Lek        ISSN： 0032-3756


× No keyword cloud information.
  5 in total

1.  Intravenous antazoline, a first-generation antihistaminic drug with antiarrhythmic properties, is a suitable agent for pharmacological cardioversion of atrial fibrillation induced during pulmonary vein isolation due to the lack of influence on atrio-venous conduction and high clinical effectiveness (AntaEP Study).

Authors:  Michal M Farkowski; Aleksander Maciag; Ilona Kowalik; Marek Konka; Hanna Szwed; Mariusz Pytkowski
Journal:  Br J Clin Pharmacol       Date:  2019-05-23       Impact factor: 4.335

Review 2.  Anti-Arrhythmic Agents in the Treatment of Atrial Fibrillation.

Authors:  Omar F Hassan; Jassim Al Suwaidi; Amar M Salam
Journal:  J Atr Fibrillation       Date:  2013-06-30

3.  Antazoline-insights into drug-induced electrocardiographic and hemodynamic effects: Results of the ELEPHANT II substudy.

Authors:  Roman Piotrowski; Joanna Giebułtowicz; Jakub Baran; Agnieszka Sikorska; Dagmara Gralak-Łachowska; Małgorzata Soszyńska; Piotr Wroczyński; Piotr Kułakowski
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-02-25       Impact factor: 1.468

4.  Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation--a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study).

Authors:  Michal M Farkowski; Aleksander Maciag; Rafal Dabrowski; Mariusz Pytkowski; Ilona Kowalik; Hanna Szwed
Journal:  Trials       Date:  2012-09-11       Impact factor: 2.279

5.  Development and Performance Verification of the PBPK Model for Antazoline and Its Metabolite and Its Utilization for Pharmacological Hypotheses Formulating.

Authors:  Barbara Wiśniowska; Joanna Giebułtowicz; Roman Piotrowski; Piotr Kułakowski; Sebastian Polak
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.